TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 140 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $68,240,853 | -37.6% | 7,633,205 | +7.3% | 0.00% | -33.3% |
| Q2 2023 | $109,315,859 | -19.6% | 7,116,918 | +17.7% | 0.00% | -25.0% |
| Q1 2023 | $136,017,631 | +27.0% | 6,047,916 | +18.7% | 0.00% | +33.3% |
| Q4 2022 | $107,134,979 | -4.7% | 5,094,388 | +11.6% | 0.00% | -25.0% |
| Q3 2022 | $112,476,000 | +3.1% | 4,564,750 | +1.4% | 0.00% | +33.3% |
| Q2 2022 | $109,096,000 | -5.6% | 4,502,577 | +0.4% | 0.00% | 0.0% |
| Q1 2022 | $115,585,000 | -17.5% | 4,485,298 | -0.7% | 0.00% | -25.0% |
| Q4 2021 | $140,152,000 | +26.7% | 4,515,145 | -1.0% | 0.00% | +33.3% |
| Q3 2021 | $110,648,000 | +51.9% | 4,562,850 | -8.6% | 0.00% | +50.0% |
| Q2 2021 | $72,840,000 | -39.6% | 4,992,525 | +3.3% | 0.00% | -50.0% |
| Q1 2021 | $120,645,000 | -8.3% | 4,831,555 | +0.1% | 0.00% | 0.0% |
| Q4 2020 | $131,510,000 | – | 4,825,174 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |